Arnab K Chatterjee

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/82190/arnab-k-chatterjee-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	4,847 citations	37 h-index	69 g-index
71 ext. papers	5,889 ext. citations	11.5 avg, IF	4.95 L-index

#	Paper	IF	Citations
66	Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19 **2021**,		53
65	Discovery and SAR studies of 3-amino-4-(phenylsulfonyl)tetrahydrothiophene 1,1-dioxides as non-electrophilic antioxidant response element (ARE) activators. *Bioorganic Chemistry*, **2021**, 108, 104614	5.1	2
64	YAP-dependent proliferation by a small molecule targeting annexin A2. *Nature Chemical Biology*, **2021**, 17, 767-775	11.7	6
63	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. *Nature Communications*, **2021**, 12, 3309	17.4	25
62	Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. *Journal of the American Chemical Society*, **2021**, 143, 13044-13055	16.4	9
61	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals **2020**,		40
60	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. *Nature*, **2020**, 586, 113-119	50.4	405
59	Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. *Science*, **2020**, 369, 993-999	33.3	94
58	2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles. *Journal of the American Chemical Society*, **2020**, 142, 8972-8979	16.4	30
57	Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections. *Science Translational Medicine*, **2019**, 11,	17.5	22
56	The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors. *Antiviral Research*, **2019**, 169, 104558	10.8	23
55	Neratinib protects pancreatic beta cells in diabetes. *Nature Communications*, **2019**, 10, 5015	17.4	21
54	Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. *Angewandte Chemie - International Edition*, **2018**, 57, 3478-3482	16.4	28
53	Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 6834-6839	11.5	44
52	The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10750-10755	11.5	97
51	A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. *Nature*, **2018**, 562, 600-604	50.4	116
50	Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs. *Cell Chemical Biology*, **2018**, 25, 1086-1094.e7	8.2	44

49	Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6920-E6926	11.5	39
48	Decarboxylative borylation. *Science*, **2017**, 356,	33.3	244
47	Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4679-4684	11.5	42
46	Small molecule selectively suppresses MYC transcription in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3497-3502	11.5	20
45	Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule. *ACS Chemical Biology*, **2017**, 12, 2715-2719	4.9	38
44	Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. *Angewandte Chemie*, **2017**, 129, 13191-13195	3.6	0
43	Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. *Angewandte Chemie - International Edition*, **2017**, 56, 13011-13015	16.4	24
42	A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005373	4.8	68
41	Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. *FASEB Journal*, **2016**, 30, 2570-9	0.9	16
40	Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 11501-11506	11.5	22
39	Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate. *Bioconjugate Chemistry*, **2015**, 26, 2216-22	6.3	37
38	Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4453-8	11.5	190
37	Discovery of highly potent, lung-localized epithelial sodium channel inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4797-4801	2.9	11
36	Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. *ACS Chemical Biology*, **2015**, 10, 413-20	4.9	57
35	Lead identification to clinical candidate selection: drugs for Chagas disease. *Journal of Biomolecular Screening*, **2015**, 20, 101-11		22
34	Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. *PLoS Pathogens*, **2015**, 11, e1005058	7.6	37
33	Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. *Journal of Medicinal Chemistry*, **2014**, 57, 828-35	8.3	57
32	Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. *ACS Medicinal Chemistry Letters*, **2014**, 5, 947-50	4.3	24

31	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 5060-7	5.9	101
30	KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1586-95	5.9	56
29	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. *Nature Communications*, **2014**, 5, 5521	17.4	85
28	Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). *Journal of Medicinal Chemistry*, **2013**, 56, 7741-9	8.3	17
27	Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. *Journal of Medicinal Chemistry*, **2013**, 56, 8849-59	8.3	68
26	Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2510-7	11.5	150
25	Targeting Plasmodium PI(4)K to eliminate malaria. *Nature*, **2013**, 504, 248-253	50.4	291
24	Antimalarial drug discovery - approaches and progress towards new medicines. *Nature Reviews Microbiology*, **2013**, 11, 849-62	22.2	202
23	Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. *ACS Medicinal Chemistry Letters*, **2013**, 4, 451-5	4.3	30
22	Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. *Science Translational Medicine*, **2013**, 5, 214ra168	17.5	105
21	Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10282-7	11.5	55
20	A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. *ACS Chemical Biology*, **2012**, 7, 1190-7	4.9	109
19	Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. *Journal of Medicinal Chemistry*, **2012**, 55, 4244-73	8.3	75
18	Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. *Current Topics in Medicinal Chemistry*, **2012**, 12, 473-83	3	41
17	Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. *Science*, **2011**, 334, 1372-7	33.3	243
16	Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. *Molecular and Biochemical Parasitology*, **2011**, 175, 21-9	1.9	62
15	Imidazolopiperazines: hit to lead optimization of new antimalarial agents. *Journal of Medicinal Chemistry*, **2011**, 54, 5116-30	8.3	88
14	Road towards new antimalarials - overview of the strategies and their chemical progress. *Current Medicinal Chemistry*, **2011**, 18, 853-71	4.3	32

13	A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. *Nature Communications*, **2010**, 1, 57	17.4	190
12	Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4027-31	2.9	22
11	Cell-based optimization of novel benzamides as potential antimalarial leads. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6970-4	2.9	15
10	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. *Nature Chemical Biology*, **2008**, 4, 347-56	11.7	178
9	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 9059-64	11.5	361
8	Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5895-9	2.9	18
7	Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5255-8	2.9	23
6	Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2899-903	2.9	13
5	Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1486-90	2.9	15
4	Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1975-80	2.9	50
3	Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5107-11	2.9	21
2	Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5112-7	2.9	28
1	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19		10